Specifically, the work by Vasikova A et al. not only unveiled the reduced expression of IRF4 across distinct genetic subsets of CD34+ cells in both early and advanced MDS patients, but also provided crucial insights into the pivotal role of IRF4 in the pathogenesis of MDS [22]. This evidence concerns the gene CD34 and myelodysplastic syndrome.